Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-04-18
|
RHB-105 (amoxicillin, rifabutin and omeprazole) |
H. pylori infection |
3 |
RedHill Biopharma (Israel) |
Infectious diseases |
2016-04-18
|
Zebinix® (eslicarbazepine acetate) |
newly diagnosed partial-onset seizures |
3 |
Eisai (Japan) Bial (Portugal) |
CNS diseases - Neurological diseases |
2016-04-18
|
IPH4301 |
|
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2016-04-18
|
CD73 checkpoint inhibitor antibodies |
|
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2016-04-18
|
monalizumab (IPH2201) and durvalumab |
|
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2016-04-18
|
Reolysin® (pelareorep - human reovirus type 3 Dearing strain) |
multiple myeloma |
preclinical |
Oncolytics Biotech (Canada) |
Cancer - Oncology |
2016-04-18
|
Reolysin® (pelareorep - human reovirus type 3 Dearing strain) |
colorectal cancer |
preclinical |
Oncolytics Biotech (Canada) |
Cancer - Oncology |
2016-04-18
|
panel of blood-based DNA methylation biomarkers |
lung cancer |
|
Epigenomics (Germany - USA) |
Cancer - Oncology - Diagnostic |
2016-04-18
|
GSK3196165 /MOR103 |
inflammatory hand osteoarthritis |
2 |
GSK (UK) |
Inflammatory diseases - Rheumatic diseases |
2016-04-18
|
labetuzumab govitecan (IMMU-130) |
metastatic colorectal cancer |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-04-17
|
Halaven® (eribulin) |
soft tissue sarcoma |
preclinical |
Eisai (Japan) |
Cancer - Oncology |
2016-04-17
|
GS-4997 |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Gilead Sciences (USA - CA) |
Liver diseases - Hepatic diseases |
2016-04-17
|
talazoparib |
heavily pre-treated non-BRCA-mutated ovarian cancer patients |
1 |
Medivation (USA - CA) |
Cancer - Oncology |
2016-04-16
|
sofosbuvir and velpatasvir |
patients with HCV genotype 1-6 who are co-infected with HIV |
3 |
Gilead Sciences (USA - CA) |
Infectious diseases |
2016-04-16
|
sofosbuvir, velpatasvir (GS-5816) and voxilaprevir (GS-9857) |
chronic hepatitis C virus infection |
2 |
Gilead Sciences (USA - CA) |
Infectious diseases |
2016-04-16
|
simtuzumab |
NASH (non-alcoholic steatohepatitis), primary sclerosing cholangitis (PSC) |
2 |
Gilead Sciences (USA - CA) |
Liver diseases - Hepatic diseases |
2016-04-16
|
GS-9674 |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Gilead Sciences (USA - CA) |
Liver diseases - Hepatic diseases |
2016-04-13
|
MIS416 |
secondary progressive multiple sclerosis |
2 |
Innate Immunotherapeutics (Australia) |
Autoimmune diseases - Neurodegenerative diseases |
2016-04-12
|
WT1-TCR T cell therapy |
myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) |
1-2 |
Cell and Gene Therapy Catapult (UK) Imperial Innovations (UK) University College London Business (UK) |
Cancer - Oncology |
2016-04-12
|
APD371 |
pain |
1b |
Arena Pharmaceuticals (USA - CA) |
CNS diseases |